Journal of Affective Disorders
January 28, 2026
Clara De Oliveira Lapa, Thiago Viola, Rodrigo Delfino et al.
3 citations
Intranasal esketamine has demonstrated efficacy and safety for treatment-resistant depression in randomized controlled trials, however the generalizability of these findings to clinical practice remains unclear. This systematic review and meta-analysis aimed to synthesize real-world evidence of intranasal esketamine in patients with treatment-resistant depression. A systematic search was...
Journal of Contextual Behavioral Science
July 1, 2025
Oscar Soto-Angona, Amanda Rodríguez‐Urrutia, Josep Antoni Ramos‐quiroga et al.
1 citation
Altres ajuts: acords transformatius de la UAB
The European Journal of Psychiatry
May 2, 2025
Josep Antoni Ramos‐quiroga, Fernando Mora, Silvia Arostegui et al.
4 citations
Pharmacological management of major depressive disorder has traditionally relied on antidepressants targeting the monoaminergic pathway. Treatment-resistant depression (TRD) patients have been frequently excluded from registrational trials, resulting in a lack of clear clinical recommendations for an optimised management. In recent years, treatments based on other mechanisms of action have been...
Advances in Therapy
May 1, 2025
Patricio Molero, Angela Ibañez, Javier de Diego-Adeliño et al.
8 citations
The INTEGRATE study aimed to provide information on the use, effectiveness, and safety of esketamine nasal spray (ESK-NS) for the treatment of treatment-resistant depression (TRD) in real-world practice in Spain. This was an observational, cross-sectional, retrospective study conducted in adults aged 18-74 years who met the criteria for TRD. The weekly impact of ESK-NS on depressive symptoms...
Journal of psychopharmacology (Oxford, England)
2025
Luis Gutiérrez-Rojas, Julia Vendrell-Serres, Josep Antoni Ramos‐quiroga et al.
8 citations
Treatment-resistant depression (TRD) is defined as the failure of at least two antidepressants in adequate doses and timing during a major depressive episode. Esketamine intranasal (ESK-IN) has been approved by the Food and Drug Administration and the European Medicines Agency for the treatment of TRD in combination with other antidepressants. To assess the effectiveness and tolerability of a...
The World Journal of Biological Psychiatry
November 3, 2020
Siegfried Kasper, Wiesław Jerzy Cubała, Andrea Fagiolini et al.
84 citations
OBJECTIVES: -methyl-d-aspartate (NMDA) glutamate receptor antagonist, is a novel, fast-acting option in this patient population. This manuscript provides expert guidance on the practicalities of using esketamine nasal spray. METHODS: A group of six European experts in major depressive disorder (MDD) and TRD, with clinical experience of treating patients with esketamine nasal spray, first...